Astellas Pharma Inc.
ALPMF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.26 | -2.16 | -1.83 | 8.49 |
| FCF Yield | 5.22% | 2.96% | 6.93% | 5.19% |
| EV / EBITDA | 13.18 | 19.03 | 9.70 | 11.36 |
| Quality | ||||
| ROIC | 2.62% | 0.63% | 5.45% | 9.65% |
| Gross Margin | 81.74% | 81.76% | 81.01% | 80.48% |
| Cash Conversion Ratio | 6.23 | 10.12 | 2.48 | 1.64 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.99% | 7.35% | 6.72% | -0.12% |
| Free Cash Flow Growth | 52.46% | -62.39% | 32.17% | -21.10% |
| Safety | ||||
| Net Debt / EBITDA | 2.59 | 3.44 | -0.52 | -0.35 |
| Interest Coverage | 2.32 | 2.13 | 15.15 | 44.46 |
| Efficiency | ||||
| Inventory Turnover | 1.17 | 1.18 | 1.65 | 1.65 |
| Cash Conversion Cycle | 235.10 | 201.06 | 146.09 | 139.92 |